Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

Mark Lipstein, Owen O'Connor, Francesca Montanari, Luca Paoluzzi, Danielle Bongero, Govind Bhagat

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

Original languageEnglish (US)
Pages (from-to)E43-E46
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number5
StatePublished - Oct 2010
Externally publishedYes


  • Diffuse large B-cell lymphoma
  • Non-Hodgkin lymphoma
  • R-CHOP

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma'. Together they form a unique fingerprint.

Cite this